OX40 inhibitors may transform atopic dermatitis landscape
The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry.
While biologics like dupilumab have already transformed care, emerging drug classes such as OX40 inhibitors are showing promise in clinical trials. Their potential for long-lasting efficacy and favorable safety profiles may significantly advance treatment options for moderate-to-severe AD patients, says GlobalData, a leading data and pharma analytics company GlobalData.
GlobalData’s report, “Atopic Dermatitis (AD) Epidemiology Analysis and Forecast to 2033,” reveals that the diagnosed prevalent cases of AD will register an annual growth rate of less than 1% during 2023-2033 across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze